0000-0002-6946-1097
Centre of Excellence for Long acting Therapeutics (CELT)
The Centre of Excellence in Long-acting Therapeutics (CELT) is a cross-faculty research initiative combining our world leading expertise in pharmacology and materials chemistry and working with international partners to disseminate research findings in long-acting medicine and change the global landscape of drug administration. - Further information and the CELT website can be found here - CELT
Rannard Group related Spinouts
LINKS:
Research from the Rannard Group and numerous collaborations has generated >150 nationally granted patents leading to commercialisation opportunities through licensing and spin-out company creation. Four spin-out/start-up companies have been created over the years, namely IOTA NanoSolutions Ltd (2005-2013), Hydra Polymers Ltd (purchased by Parogle Technologies), Tandem Nano Ltd and, most recently, Polymer Mimetics as a joint venture with Scott Bader. The group continues to develop novel technologies with the potential for economic and societal impact.
Functional Materials Team
The growing organic materials and nanomedicine activities within the Department of Chemistry and the Materials Innovation Factory at Liverpool has led to a cross-Group working collaboration (created in 2020) to build and support new technology development. This comprises Professor Steve Rannard, Dr Tom McDonald, Dr Marco Giardiello and Dr Helen Cauldbeck (a research Fellow within the Rannard group).
The strengths of the Team include polymer synthesis, polymer chemistry, colloid science, inorganic chemistry, organic and inorganic nanoparticles, nanocomposites, nanomedicine, radiochemistry and diagnostics. Within the Rannard group, the research themes of Polymer Technologies, Active Colloids and the Radio Materials Laboratory aim to develop fundamental understanding and routes to technology commercialisation.
LINKS:
The UoL Nanomedicine Parnership
An academic partnership was created in 2009 across the Faculties of Health & Life Science and Science & Engineering at the University of Liverpool to collectively progress fundamental nanomedicine research towards clinical demonstration and the realisation of patient benefits. Initially comprising Professor Andrew Owen (pharmacology) and Professor Steve Rannard (materials chemistry), the partnership has grown to also include Dr Tom McDonald (chemistry), Dr Neill Liptrott (pharmcology), Dr Marco Giardiello (chemistry) and Dr Marco Siccardi (pharmacology) and is mainly co-located in the Materials Innovation Factory.
Along with collaborations with the Johns Hopkins Medical School (Baltimore), the partnership has been instrumental in generating the foundations for the British Society for Nanomedicine, the UK core for the European Nanomedicine Characterisation Laboratory and the Journal of Interdisciplinary Nanomedicine (Wiley). Outputs from the partnership also include the first human trials of an orally dosed antiretroviral therapy for HIV treatment and demonstration of the potential for long acting nanoparticle depot injections to enable malaria prophylaxis. The partnership also signed the first academic technology access contract with the UNITAID-funded Medicines Patent Pool.
LINKS:
